Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30.

We studied 31 nondiabetic, habitually (> or =5 years) morbidly obese subjects (mean +/- SD body mass index [BMI] 43 +/- 8.7, median 43). Our specific aim was to determine whether metformin (2.55 g/d for 28 weeks) would ameliorate morbid obesity and reduce centripetal obesity; lipid and lipoprotein cholesterol, insulin, and leptin levels; and plasminogen activator inhibitor activity (PAI-Fx), risk factors for coronary heart disease (CHD). The patients were instructed to continue their prestudy dietary and exercise regimens without change. After 2 baseline visits 1 week apart, the 27 women and 4 men began receiving metformin, 2.55 g/d, which was continued for 28 weeks with follow-up visits at study weeks 5, 13, 21, and 29. Daily food intake was recorded by patients for 7 days before visits then reviewed with a dietitian. Kilocalories per day and per week were calculated. At each visit, fasting blood was obtained for measurement of lipid profile, insulin, leptin, and PAI-Fx. The mean +/- SD kilocalories consumed per day, 1,951 +/- 661 at entry, fell by week 29 to 1,719 +/- 493 (P =.014) but did not differ at weeks 5, 13, and 21 from that at week 29 (P >.2). Weight fell from 258 +/- 62 pounds at entry to 245 +/- 54 pounds at week 29 (P =.0001). Girth was reduced from 51.8 +/- 6.2 to 49.2 +/- 4.5 inches (P =.0001). Waist circumference fell from 44.0 +/- 6.4 inches to 41.3 +/- 5.9 (P =.0001). The waist/hip ratio fell from 0.85 +/- 0.09 to 0.84 +/- 0.09 (P =.04). Fasting serum insulin, 28 +/- 15 microU/mL at entry, fell to 21 +/- 11 microU/mL at week 29 (P =.0001), and leptin fell from 79 +/- 33 ng/mL to 55 +/- 27 ng/mL (P =.0001). On metformin, there were linear trends in decrements in weight, girth, waist circumference, waist/hip ratio, insulin, and leptin throughout the study period (P <.007). Low-density lipoprotein (LDL) cholesterol, 126 +/- 34 mg/dL at study entry, fell to 112 +/- 43 mg/dL at week 29 (P =.001), with a linear trend toward decreasing levels throughout (P =.036). By stepwise linear regression, the higher the entry weight, the larger the reduction in weight on metformin therapy (partial R(2) = 31%, P =.001). The greater the reduction in kilocalories consumed per day, the greater the decrease in weight on metformin therapy (partial R(2) = 15%, P =.011). The higher the waist/hip ratio at entry, the greater its reduction on metformin therapy (partial R(2) = 11%, P =.004). The higher the entry serum leptin, the greater its reduction on metformin therapy (partial R(2) = 29%, P =.002). The greater the reduction in insulin on metformin, the greater the reduction in leptin (partial R(2) = 8%, P =.03). The higher the entry PAI-Fx, the greater the reduction in PAI-Fx on metformin (partial R(2) = 43%, P =.0001). Metformin safely and effectively reduces CHD risk factors (weight, fasting insulin, leptin, LDL cholesterol, centripetal obesity) in morbidly obese, nondiabetic subjects with BMI > 30, probably by virtue of its insulin-sensitizing action.

[1]  P. Bennett,et al.  The natural history of impaired glucose tolerance in the Pima Indians. , 1988, The New England journal of medicine.

[2]  M. Laakso,et al.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. , 1998, The New England journal of medicine.

[3]  J. Gerich,et al.  The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. , 1998, Endocrine reviews.

[4]  C. Glueck,et al.  Relationships between lipoprotein(a), lipids, apolipoproteins, basal and stimulated fibrinolytic regulators, and D-dimer. , 1993, Metabolism: clinical and experimental.

[5]  A. Goldberg,et al.  Leptin responses to weight loss in postmenopausal women: relationship to sex-hormone binding globulin and visceral obesity. , 2000, Obesity research.

[6]  A. Folsom,et al.  A Prospective Study of Coronary Heart Disease in Relation to Fasting Insulin, Glucose, and Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study , 1997, Diabetes Care.

[7]  S Fiorini,et al.  Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. , 2000, The Journal of clinical endocrinology and metabolism.

[8]  S. Kiechl,et al.  Relationship between insulin and carotid atherosclerosis in the general population. The Bruneck Study. , 1997, Stroke.

[9]  K. Fujioka,et al.  Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. , 1999, JAMA.

[10]  S. Srinivasan,et al.  Persistent elevation of plasma insulin levels is associated with increased cardiovascular risk in children and young adults. The Bogalusa Heart Study. , 1996, Circulation.

[11]  S. Wannamethee,et al.  Weight change and duration of overweight and obesity in the incidence of type 2 diabetes. , 1999, Diabetes care.

[12]  M. Laakso,et al.  How good a marker is insulin level for insulin resistance? , 1993, American journal of epidemiology.

[13]  P. Tounian,et al.  Weight loss and changes in energy metabolism in massively obese adolescents , 1999, International Journal of Obesity.

[14]  C. Glueck,et al.  Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. , 1999, Metabolism: clinical and experimental.

[15]  B. Baranowska,et al.  Neuropeptide Y, leptin, galanin and insulin in women with polycystic ovary syndrome. , 1999, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[16]  R. J. Hayes,et al.  United Kingdom Prospective Diabetes Study 24: A 6-Year, Randomized, Controlled Trial Comparing Sulfonylurea, Insulin, and Metformin Therapy in Patients with Newly Diagnosed Type 2 Diabetes That Could Not Be Controlled with Diet Therapy , 1998, Annals of Internal Medicine.

[17]  A. Hamsten,et al.  Progression of coronary artery disease in young male post-infarction patients is linked to disturbances of carbohydrate and lipoprotein metabolism and to impaired fibrinolytic function. , 1998, European heart journal.

[18]  A. Goris,et al.  Undereating and underrecording of habitual food intake in obese men: selective underreporting of fat intake. , 2000, The American journal of clinical nutrition.

[19]  Jeppesen,et al.  Individuals with high total cholesterol/hdl cholesterol ratios are insulin resistant , 1998, Journal of internal medicine.

[20]  S. Haffner,et al.  Prospective Analysis of The Insulin-Resistance Syndrome (Syndrome X) , 1992, Diabetes.

[21]  E. Bonora,et al.  Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. , 1989, The New England journal of medicine.

[22]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[23]  K. Yano,et al.  Hyperinsulinemia and cardiovascular disease in elderly men: the Honolulu Heart Program. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[24]  P. Zimmet,et al.  Etiology of the Metabolic Syndrome: Potential Role of Insulin Resistance, Leptin Resistance, and Other Players , 1999, Annals of the New York Academy of Sciences.

[25]  A. Ruokonen,et al.  Decreased serum leptin concentrations during metformin therapy in obese women with polycystic ovary syndrome. , 1998, The Journal of clinical endocrinology and metabolism.

[26]  P. Maheux,et al.  The degree of hyperinsulinemia and impaired glucose tolerance predicts plasma leptin concentrations in women only: a new exploratory paradigm. , 2000, Metabolism: clinical and experimental.

[27]  H. Hauner.  The impact of pharmacotherapy on weight management in type 2 diabetes , 1999, International Journal of Obesity.

[28]  J. Morley,et al.  Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. , 1998, Obesity research.

[29]  A. Duleba,et al.  Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. , 2000, Fertility and sterility.

[30]  A. Inui,et al.  Cancer anorexia-cachexia syndrome: are neuropeptides the key? , 1999, Cancer research.

[31]  C. Glueck,et al.  Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. , 1997, Metabolism: clinical and experimental.